Innoviva Q1 net income $36.5M ($0.58 basic EPS); product sales up 66% YoY to $19.1M; GSK royalties $61.9M

Innoviva, Inc.

2024-Q1 EPS reported $0.46 revenue$77,499,000

Net income $36.5M ($0.58 basic EPS) vs $34.9M ($0.51) in Q1 2023.
Net product sales $19.1M, +66% YoY, driven by XACDURO launch and GIAPREZA growth.
GSK royalty revenue $61.9M, up from $60.3M in Q1 2023.
Repurchased 0.6M shares for $9.7M in Q1 2024; completed $5.3M buyback post-quarter.
Positive Phase 3 zoliflodacin results for uncomplicated gonorrhea; NDA submission expected early 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Innoviva, Inc. reported first quarter ended March 31, 2024 results: net income $36.5 million, or $0.58 basic per share.

Period: first quarter ended March 31, 2024
Net income: $36.5 million, or $0.58 basic per share
Result: reported results

Exact text from the filing

Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2024.

View on SEC.gov

Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-058747

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.